Trial Profile
Relapse Prophylaxis With IL-15 Super Agonist N-803 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Following Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2023
Price :
$35
*
At a glance
- Drugs Inbakicept (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms QUILT-3.035
- 04 Jan 2023 Status changed from active, no longer recruiting to completed.
- 25 Feb 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.
- 25 Feb 2022 Status changed from recruiting to active, no longer recruiting.